dc.contributor.author
Klimek, Ludger
dc.contributor.author
Bergmann, Karl-Christian
dc.contributor.author
Brehler, Randolf
dc.contributor.author
Pfützner, Wolfgang
dc.contributor.author
Zuberbier, Torsten
dc.contributor.author
Hartmann, Karin
dc.contributor.author
Jakob, Thilo
dc.contributor.author
Novak, Natalija
dc.contributor.author
Ring, Johannes
dc.contributor.author
Merk, Hans
dc.contributor.author
Hamelmann, Eckard
dc.contributor.author
Ankermann, Tobias
dc.contributor.author
Schmidt, Sebastian
dc.contributor.author
Untersmayr, Eva
dc.contributor.author
Hötzenecker, Wolfram
dc.contributor.author
Jensen-Jarolim, Erika
dc.contributor.author
Brockow, Knut
dc.contributor.author
Mahler, Vera
dc.contributor.author
Worm, Margitta
dc.date.accessioned
2023-06-12T13:47:49Z
dc.date.available
2023-06-12T13:47:49Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/39806
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-39526
dc.description.abstract
Background: For the preventive treatment of the 2019 coronavirus disease (COVID-19) an unprecedented global research effort studied the safety and efficacy of new vaccine platforms that have not been previously used in humans. Less than one year after the discovery of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral sequence, these vaccines were approved for use in the European Union (EU) as well as in numerous other countries and mass vaccination efforts began. The so far in the EU approved mRNA vaccines BNT162b2 and mRNA-1273 are based on similar lipid-based nanoparticle carrier technologies; however, the lipid components differ. Severe allergic reactions and anaphylaxis after COVID-19 vaccination are very rare adverse events but have drawn attention due to potentially lethal outcomes and have triggered a high degree of uncertainty.
Methods: Current knowledge on anaphylactic reactions to vaccines and specifically the new mRNA COVID-19 vaccines was compiled using a literature search in Medline, PubMed, as well as the national and international study and guideline registries, the Cochrane Library, and the Internet, with special reference to official websites of the World Health Organization (WHO), US Centers for Disease Control and Prevention (CDC), Robert Koch Institute (RKI), and Paul Ehrlich Institute (PEI).
Results: Based on the international literature and previous experience, recommendations for prophylaxis, diagnosis and therapy of these allergic reactions are given by a panel of experts.
Conclusion: Allergy testing is not necessary for the vast majority of allergic patients prior to COVID-19 vaccination with currently licensed vaccines. In case of allergic/anaphylactic reactions after vaccination, allergy workup is recommended, as it is for a small potential risk population prior to the first vaccination. Evaluation and approval of diagnostic tests should be done for this purpose.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Allergic reaction
en
dc.subject
Anaphylactic reaction
en
dc.subject
Corona virus
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Practical handling of allergic reactions to COVID-19 vaccines
dc.type
Wissenschaftlicher Artikel
dc.title.subtitle
A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and ÖGAI
dcterms.bibliographicCitation.doi
10.1007/s40629-021-00165-7
dcterms.bibliographicCitation.journaltitle
Allergo Journal International
dcterms.bibliographicCitation.number
3
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
79
dcterms.bibliographicCitation.pageend
95
dcterms.bibliographicCitation.volume
30
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
33898162
dcterms.isPartOf.eissn
2197-0378